Is Buying Bioshares Biotechnology Clinical (NYSEARCA:BBC), Having Higher Short Interest a Winning Strategy?

January 13, 2018 - By Marguerite Chambers

 Is Buying Bioshares Biotechnology Clinical (NYSEARCA:BBC), Having Higher Short Interest a Winning Strategy?

The stock of Bioshares Biotechnology Clinical (NYSEARCA:BBC) registered an increase of 3.25% in short interest. BBC’s total short interest was 126,900 shares in January as published by FINRA. Its up 3.25% from 122,900 shares, reported previously. With 7,700 shares average volume, it will take short sellers 17 days to cover their BBC’s short positions.

The ETF increased 1.44% or $0.439 during the last trading session, reaching $30.949. About 11,208 shares traded. Virtus LifeSci Biotech Clinical Trls ETF (NYSEARCA:BBC) has risen 20.72% since January 13, 2017 and is uptrending. It has outperformed by 4.02% the S&P500.

More notable recent Virtus LifeSci Biotech Clinical Trls ETF (NYSEARCA:BBC) news were published by: Marketwatch.com which released: “Virtus LifeSci Biotech Clinical Trials ETF” on December 16, 2014, also Benzinga.com with their article: “Life (Science) Lessons: The Hows And Whos To Play Biotech” published on October 06, 2017, Nasdaq.com published: “Best Sector ETF of Q3 and its Top-Performing Stocks” on October 02, 2017. More interesting news about Virtus LifeSci Biotech Clinical Trls ETF (NYSEARCA:BBC) were released by: Nasdaq.com and their article: “The Zacks Analyst Blog Highlights: Virtus LifeSci Biotech Clinical, SPDR S&P …” published on December 27, 2017 as well as Prnewswire.com‘s news article titled: “Virtus ETF Solutions Rebrands BioShares ETFs; Moves Listings for BBC, BBP to …” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.